Telomir Pharmaceuticals, Inc. Common Stock
TELOTelomir Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing products that target aging and age-related diseases through telomere biology. The company aims to leverage telomere science to create innovative therapies for extending healthspan and lifespan.
Company News
U.S. stock futures fell on Tuesday, with market attention focused on potential Federal Reserve rate cuts and ongoing government shutdown. Key companies like AMD and Trilogy Metals saw significant stock movements due to strategic developments.
TAMPA, Fla., July 02, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps as a potential treatment fo...
Drug Information Association (DIA) 2024 is the largest global, multidisciplinary event for the professionals involved in the discovery, development, and lifecycle management of pharmaceuticals, biotechnology, medical devices, and related products Drug Information Association (DIA) 2024 is the largest global, multidisciplinary event for the profes...
Commences the study, The Safety of Telomir-1 when Administered Orally to Geriatric Laboratory Beagle Dogs for 63 Consecutive Days study to evaluate the safety of Telomir-1 on geriatric canines
Telomir-1 elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase that protects the DNA and genetic material in chromosomes to combat aging
